[Problems in the therapy of ovarian carcinoma with gestagen-acting hormones]
- PMID: 6880471
[Problems in the therapy of ovarian carcinoma with gestagen-acting hormones]
Abstract
Our experience concerning the effectivity of progestogens (Noräthisteron 50 mg per os daily) in cases of advanced ovarian cancer is reported. Group 1 (25 pat.) suffering from less sensitive ovarian cancer was treated with cytotoxic drugs and hormones. The survival chance of combined hormonal and tumourchemotherapy was nearly 40% better than the survival chance with chemotherapy alone. In Group 2 (14 pat.) suffering from secondary resistant ovarian cancer chemotherapy was stopped, but the patients received hormones only. There were no better survival rate in this group. The biomolecular background is explained.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical